Cited by 797SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesT-cell and B-cell Immunology

T cell responses in patients with COVID-19

Open access
Chen, Zeyu, John Wherry, E.·2020·Nature Reviews Immunology

Abstract

The role of T cells in the resolution or exacerbation of COVID-19, as well as their potential to provide long-term protection from reinfection with SARS-CoV-2, remains debated. Nevertheless, recent studies have highlighted various aspects of T cell responses to SARS-CoV-2 infection that are starting to enable some general concepts to emerge.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41577-020-0402-6

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • For SARS-CoV-2, increasing evidence indicates that T cells play a major role in the resolution of COVID-19.

    “For SARS-CoV-2, increasing evidence indicates that T cells play a major role in the resolution of COVID-19,28, 29”

    From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [29]

    The Conclusions (page unavailable) say accumulating evidence supports a role for T cells in COVID-19. But the Abstract says their role in resolving or exacerbating disease remains debated, and the CD8+ T cell section says an association with recovery may be a cause or a consequence. The source therefore does not establish a major role in resolution. (LLM, conf=0.87)

    Experimental — accuracy not yet measured
  • Following infection, both lower and higher CD8+ and CD4+ T cell responses have been reported.

    “Both reduced and increased CD8+ and CD4+ T cell responses have been observed following infection41.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 7

  1. [7]Wilk AJ A single-cell atlas of the peripheral immune response in patients with severe COVID-19 Nat. Med. 2020 26 1070 1076 32514174 PMC7382903
  2. [8]Mathew D Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications Science 2020 10.1126/science.abc8511 32669297 PMC7402624 · DOI · Paper page
  3. [16]Wichmann D Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study Ann. Intern. Med. 2020 10.7326/M20-2003 32374815 PMC7240772 · DOI
  4. [25]Yu K Thymosin α-1 protected T cells from excessive activation in severe COVID-19 Research Square 2020 10.21203/rs.3.rs-25869/v1 · DOI
  5. [60]Takahashi T Sex differences in immune responses to SARS-CoV-2 that underlie disease outcomes medRxiv 2020 10.1101/2020.06.06.20123414 32995811 PMC7523150 · DOI
  6. [78]Guo C Tocilizumab treatment in severe COVID-19 patients attenuates the inflammatory storm incited by monocyte centric immune interactions revealed by single-cell analysis bioRxiv 2020 10.1101/2020.04.08.029769 · DOI
  7. [81]Goldman-Israelow B Song E Mao T Lu P Meir A Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling bioRxiv 2020 10.1101/2020.05.27.118893 PMC7401025 32750141 · DOI

Cited by

Sorted by citations

Authors
Chen, Z., & John Wherry, E.
Affiliations
University of Pennsylvania (US)
Venue
Nature Reviews Immunology
Published
2020-07-29
Volume
20
Issue
9
Pages
529-536
ISSN
  • 1474-1733 (ISSN-L)
  • 1474-1741
OpenAlex
W3046194290
Cited by
797
References
79
Citations by year
2026: 17 · 2025: 41 · 2024: 63 · 2023: 97 · 2022: 191 · 2021: 305 · 2020: 83
FWCI
8.02
Type
journal article
Language
en
Open access
Locations
  • Nature reviews. Immunology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Parker Institute for Cancer Immunotherapy
  • Allen Institute for Immunology
  • National Institutes of Health (CA234842, AI082630)
  • National Cancer Institute (K00CA234842, F99CA234842)
  • National Institute of Allergy and Infectious Diseases (U19AI082630)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
T cell response, COVID-19 pandemic, SARS-CoV-2, disease phenotypes, immune response heterogeneity, reinfection protection, disease severity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review